Document is current
Any future updates will be listed below
-
Authors
Trojan, Jörg https://orcid.org/0000-0001-9414-378X
Mollon, Patrick
Daniele, Bruno https://orcid.org/0000-0002-2638-3156
Marteau, Florence
Martín, Lidia
Li, Yuxin
Xu, Qing
Piscaglia, Fabio https://orcid.org/0000-0001-8264-1845
Zaucha, Renata https://orcid.org/0000-0001-8503-1559
Sarker, Debashis https://orcid.org/0000-0003-4814-8429
Lim, Ho Yeong https://orcid.org/0000-0001-9325-2300
Venerito, Marino https://orcid.org/0000-0001-8581-0974
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01908426 at ClinicalTrials.govnct02435433 at ClinicalTrials.govDocuments that mention this clinical trial
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-021-01700-2
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
https://doi.org/10.1136/esmoopen-2020-000714
Documents that mention this clinical trial
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-021-01700-2
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
https://doi.org/10.1136/esmoopen-2020-000797
-
Funding
Funding for this research was provided by:
Ipsen
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 21 December 2020
Accepted: 6 March 2021
First Online: 6 April 2021
